One Transcript Is Not the Same Risk as Several Promoters

A multiplex gRNA array versus separate expression cassettes is a packaging split, not a nuclease brand. An array is usually one transcript that carries several spacers. Separate cassettes are usually several promoters, each driving one guide. Prefer an array when the nuclease can process that transcript. Prefer separate cassettes when each guide must be independently tunable. Reject “it is multiplex, so the plasmid is the same.”

Zetsche et al., 2015 describe Cpf1/Cas12a as an enzyme that can process CRISPR arrays from a single RNA. Cas12a direct repeat versus Cas9 scaffold still owns guide architecture. Batch sgRNA design software still owns library-scale tools. This page only names how several guides sit on one plasmid. Do not invent a universal multiplex efficiency. Published array systems report their own conditions. Those numbers are paper-specific, not an official Zetta rate.

One Transcript Is Not the Same Risk as Several Promoters

The search compares a multiplex gRNA array with separate cassettes. The entities are layouts. In an array, spacers sit in one RNA, often separated by repeats that a nuclease or accessory activity can cleave. If that processing step fails, several guides can fail together. In separate cassettes, each guide has its own promoter and terminator. If one promoter silences, the others can still fire. That independence is also a new risk: several promoters can interfere, compete for polymerase, or differ in strength so the “multiplex” plasmid is really one strong guide plus passengers.

Cas9 multiplex plasmids commonly use several U6-class cassettes because classic Cas9 does not process a CRISPR array the way Cas12a can. Cas12a can make an array practical because array processing is a property of that nuclease. The property does not decide the packaging for you. You can still put Cas12a guides in separate cassettes. You can still attempt a Cas9 array with extra processing tricks. Those are later design choices. The first distinction is one transcript versus several promoters.

Where the Failure Modes Diverge

Score both layouts on the same operational labels. This is not a vendor table.

Prefer the array when you want one transcriptional decision and the nuclease is known to process the repeat architecture you cloned. Prefer separate cassettes when you must shut one guide off, swap one spacer without rebuilding the array, or use a nuclease that does not process arrays. Reject a mixed sentence that calls both “the multiplex plasmid” as if dropout risk were identical. A single bright band on a digest does not prove every spacer is expressed.

Do not convert this table into a Cas12a-versus-Cas9 rank. Nuclease choice can make an array easier. It does not replace the packaging decision. Pre-cloning CRISPR map review still owns PAM, marker, and promoter checks before anyone ligates. Use that gate after the layout is named.

This Is Not the Nuclease-Architecture Page

Cas12a direct repeats versus a Cas9 scaffold is a different object. That sibling explains why a Cas9 sgRNA cassette will not feed Cas12a. This page assumes you already know which guide chemistry you are cloning. Batch sgRNA software is also a different object. Designing a hundred spacers is not the same as deciding whether those spacers ride one transcript or several promoters. If the reader is choosing a library-design tool, leave. If the reader is choosing DR versus scaffold, leave. Stay here only for packaging.

Golden Gate is not a Zetta feature. Do not describe array assembly as a Zetta product workflow. Assembly chemistry, if mentioned at all, is a lab method, not a software claim.

A worked layout choice is three spacers against one locus family. If the nuclease processes an array and the lab wants one Pol III decision, the plasmid can carry one promoter and a repeat-separated array. If one spacer later proves toxic or off-plan, rebuilding the array is the cost of that choice. If the lab already knows it may drop spacer 2 after a pilot, three separate cassettes let that spacer be silenced or swapped without rewriting the other two. Neither layout is “more multiplex.” They are different dropout geometries. Write the geometry on the map before anyone orders oligos.

Name the Spacers After the Layout Is Chosen

Name the layout before anyone treats a multiplex badge as a map. After the architecture is chosen, a design surface such as ZettaCRISPR can hold named spacers and related primer-design work. That is a place to record the spacers you decided to package. It does not pick array versus cassette, does not process an array for you, and is not the subject of this comparison. Official product language does not invent Golden Gate as a Zetta capability.

If the map still says “multiplex” without saying one transcript or several promoters, you do not have a layout. You have a slogan. Write the packaging. Then clone. Then, if the nuclease chemistry is still unnamed, use the DR-versus-scaffold sibling.

Processing failure is a layout cost, not a spacer-score cost. If the nuclease never matures the middle guide in an array, the plasmid still looks multiplex on paper. Separate cassettes fail differently: one promoter can die while the others fire, which is a dose mismatch, not a missing mature RNA from a shared transcript. Those two failure pictures need different troubleshooting. Do not treat a bright colony as proof that every spacer is present as RNA. Sequence the junctions you claimed, then ask whether the mature guides exist. That second question is wet work. It is not a software multiplex badge.

Frequently Asked Questions

Is a multiplex array the same object as several guide cassettes?

No. An array is usually one transcript. Separate cassettes are usually several promoters. Dropout risk is not the same.

Does choosing Cas12a decide array versus cassette packaging?

No. Cas12a can process an array. Packaging is still a plasmid layout choice. Cas12a guides can also sit in separate cassettes.